Tokyo Tape
Sign in
← Chiome Bioscience

Quarterly report · Q2

4583.TEDINET S100OXYH
Period2022-01-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥278m2022-01-01 → 2022-06-30StandaloneNet sales
Revenue¥713m2021-01-01 → 2021-12-31StandaloneNet sales (5-year summary)
Revenue¥385m2021-01-01 → 2021-06-30StandaloneNet sales
Operating income−¥779m2022-01-01 → 2022-06-30StandaloneOperating income
Operating income−¥415m2021-01-01 → 2021-06-30StandaloneOperating income
Ordinary income−¥769m2022-01-01 → 2022-06-30StandaloneOrdinary income
Ordinary income−¥1.3bn2021-01-01 → 2021-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥409m2021-01-01 → 2021-06-30StandaloneOrdinary income
Profit before tax−¥769m2022-01-01 → 2022-06-30StandaloneIncome before income taxes
Profit before tax−¥397m2021-01-01 → 2021-06-30StandaloneIncome before income taxes
Net income−¥771m2022-01-01 → 2022-06-30StandaloneProfit loss
Net income−¥1.5bn2021-01-01 → 2021-12-31StandaloneNet income loss (5-year summary)
Net income−¥409m2021-01-01 → 2021-06-30StandaloneProfit loss
Total assets¥1.9bnat 2022-06-30StandaloneAssets
Total assets¥2.3bnat 2021-12-31StandaloneAssets
Total assets¥3.3bnat 2021-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥444mat 2022-06-30StandaloneLiabilities
Total liabilities¥446mat 2021-12-31StandaloneLiabilities
Net assets / equity¥1.5bnat 2022-06-30StandaloneNet assets
Net assets / equity¥1.9bnat 2021-12-31StandaloneNet assets
Net assets / equity¥2.9bnat 2021-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.5bnat 2022-06-30StandaloneCash and deposits
Cash and deposits¥1.8bnat 2021-12-31StandaloneCash and deposits
Cash & equivalents¥1.5bnat 2022-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.8bnat 2021-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.3bnat 2021-06-30StandaloneCash and cash equivalents
Cash & equivalents¥2.7bnat 2020-12-31dStandaloneCash and cash equivalents
Operating cash flow−¥660m2022-01-01 → 2022-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2021-01-01 → 2021-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥561m2021-01-01 → 2021-06-30StandaloneNet cash provided by used in operating activities
Investing cash flow−¥35m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥341m2022-01-01 → 2022-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥271m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥176m2021-01-01 → 2021-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-18.172022-01-01 → 2022-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.532022-04-01 → 2022-06-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.742021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-10.162021-01-01 → 2021-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.162021-04-01 → 2021-06-30dStandaloneBasic earnings loss per share (5-year summary)
Equity ratio75.3%at 2022-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio79.4%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio85.3%at 2021-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued43,057,600at 2022-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued40,781,500at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued40,291,500at 2021-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-06-30−¥239m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2022-01-01 → 2022-06-30−¥691m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2022-01-01 → 2022-06-30¥278m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2022-01-01 → 2022-06-30¥278m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2022-01-01 → 2022-06-30¥151m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-06-30¥278m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-06-30¥278m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-06-30−¥540m
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-06-30−¥215m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentrevenue2021-01-01 → 2021-06-30¥103m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentrevenue external2021-01-01 → 2021-06-30¥103m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2021-01-01 → 2021-06-30−¥356m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2021-01-01 → 2021-06-30¥282m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2021-01-01 → 2021-06-30¥282m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2021-01-01 → 2021-06-30¥156m
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-06-30¥385m
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-06-30¥385m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-06-30−¥201m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 436
ItemContextValueUnit
Operating incomePrior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember-200529000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember-214815000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember-415345000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember－JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember278211000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember278211000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember278211000JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember－JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember－JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember278211000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember278211000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesCurrentYTDDuration_NonConsolidatedMember278211000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember-690981000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember151129000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember-539851000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember-239364000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember-779216000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2022-08-10
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第19期第２四半期（自　2022年４月１日　至　2022年６月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社カイオム・バイオサイエンス
Company name in english cover pageFilingDateInstantChiome Bioscience Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　小林　茂
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都渋谷区本町三丁目12番１号
Telephone number address of registered headquarter cover pageFilingDateInstant03-6383-3746
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役経営企画室長　美女平　在彦
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都渋谷区本町三丁目12番１号
Telephone number nearest place of contact cover pageFilingDateInstant03-6383-3746
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役経営企画室長　美女平　在彦
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE26096
Fund codeFilingDateInstant－
Security codeFilingDateInstant45830
Filer name in japaneseFilingDateInstant
Original text (Japanese)株式会社カイオム・バイオサイエンス
Filer name in englishFilingDateInstantChiome Bioscience Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2021-12-31pass
balance sheet identitynon_consolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-06-30pass
statement vs summary · operating cash flownon_consolidated 2021-01-01/2021-06-30pass
statement vs summary · operating cash flownon_consolidated 2022-01-01/2022-06-30pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-06-30pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-06-30pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-06-30pass